ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.

Shares of ResMed Inc. slipped 3.03% to $244.46 Friday, on what proved to be an all-around dismal trading session for the ...

ResMed, Inc. RMD recently introduced its AirCurve 11 series devices. These are the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure and expiratory ...

(MENAFN- GetNews) Air Voel, a trusted name in sleep therapy solutions and an official distributor of ResMed devices in Canada, is proud to introduce the ResMed AirSense 11 Auto, the latest advancement ...

The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ). ResMed Inc. has reported ...

ResMed’s third quarter results aligned with Wall Street’s revenue expectations, while its non-GAAP earnings per share moderately outpaced consensus. Management attributed the quarter’s performance to ...

Medical device company ResMed (NYSE:RMD) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.1% year on year ...

ResMed's first-quarter result broadly met market expectations, though rising margins and potential for further capital ...

Resmed Inc (ASX: RMD) shares are highly rated by analysts at Macquarie. Here's why the broker is bullish on this ...

The Food and Drug Administration on Thursday classified the voluntary recall of certain respiratory masks made by ResMed as “most serious” as their incorrect use could cause major injuries or death.

Resmed Inc.’s RMD adjusted earnings per share (EPS) in the first quarter of fiscal 2026 were $2.55, up 15.9% year over year.